Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience

Scandinavian Journal of Gastroenterology

Volumn 51, Issue 3, 2016, Pages 337-343

  Waldenström, Jesper ^a   Färkkilä, Martti ^b   Rembeck, Karolina ^a   Norkrans, Gunnar ^a   Langeland, Nina ^c,d   Mørch, Kristine ^d   Pedersen, Court ^e   Rauning Buhl, Mads ^f   Nieminen, Urpo ^b   Nuutinen, Hannu ^b   Alsiö, Åsa ^g   Holmström, Lars ^h   Jungnelius, Rolf ⁱ   Lund, Katarina ^j   Rubensson, Anders ^k   Torell, Erik ^l   Westin, Johan ^a   Lagging, Martin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

^g SKARABORG HOSPITAL   (Sweden)

^h Hallands Sjukhus   (Sweden)

ⁱ Infektionskliniken   (Sweden)

^j NAL Medical Centre Hospital   (Sweden)

^k Infektionskliniken   (Sweden)

^l Infektionskliniken   (Sweden)

more..

Author keywords

Genotype 2; Genotype 3; Hepatitis C virus; Inosine triphosphate pyrophosphatase; Interferon; ITPA; Ribavirin

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; CXCL10 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INORGANIC PYROPHOSPHATASE; INTERLEUKIN DERIVATIVE; ITPA PROTEIN, HUMAN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; KINETICS; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; OUTCOME ASSESSMENT; PERSONAL EXPERIENCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGE; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MIDDLE AGED; SCANDINAVIA; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGE FACTORS; ANTIVIRAL AGENTS; CHEMOKINE CXCL10; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MIDDLE AGED; POLYETHYLENE GLYCOLS; PYROPHOSPHATASES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SCANDINAVIAN AND NORDIC COUNTRIES; TREATMENT OUTCOME;

EID: 84947046966     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2015.1087588     Document Type: Article

References (24)

1. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
2. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77.
3. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014;370:222-32.
4. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21.
5. Zeuzem S, Dusheiko G, Salupere R, Mangia A, Flisiak R, Hyland R, et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013;58:733A-4A.
6. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with HCV genotype (GT) 3: ALLY-3 phase 3 study. Hepatology 2014;60:6-7.
7. Gane EJ, Huyland RH, An D, Svarovskaia ES, Pang PS, Brainard D, Stedman CA. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015. [Epub ahead of print]. doi: 10. 1053/j. gastro. 2015. 07. 063.
8. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199-236.
9. Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
10. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47:1837-45.
11. FärkkilaM. C-hepatiitin hoito: miten ja milloin? Duodecim 2010;126:41-8.
12. Lagging M, Alsio A, Langeland N, Pedersen C, Farkkila M, Buhl MR, et al. Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection. Hepatology 2011;53:1067-8.
13. Lagging M, Alsio S, Hellstrand K, Norkrans G. Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection? J Hepatol 2011;54:835-6. Author reply 6-7.
14. Lagging M, Duberg AS, Wejstal R, Weiland O, Lindh M, Aleman S, et al. Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. Scand J Infect Dis 2012;44:502-21.
15. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010;464:405-8.
16. Lagging M, Rembeck K, Waldenstrom J, Nilsson S, Nystrom K, Martner A, et al. ITPA variants are associated with reduced relapse rate but not with early virological responses following HCV genotype 2/3 therapy. Hepatology 2130;60:502-1.
17. Rembeck K, Waldenstrom J, Hellstrand K, Nilsson S, Nystrom K, Martner A, et al. Variants of the ITPase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology 2014;59:2131-9.
18. Clark PJ, Aghemo A, Degasperi E, Galmozzi E, Urban TJ, Vock DM, et al. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. J Viral Hepat 2013;20:858-66.
19. Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre M, Rees DC, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Human Genet 2002;111:360-7.
20. Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem 2006;52:240-7.
21. Maeda T, Sumi S, Ueta A, Ohkubo Y, Ito T, Marinaki AM, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab 2005;85:271-9.
22. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
23. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002;37:837-42.
24. Leutscher PD, Lagging M, Buhl MR, Pedersen C, Norkrans G, Langeland N, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010;52:430-5.